|
WO1996024358A1
(en)
*
|
1995-02-10 |
1996-08-15 |
G.D. Searle & Co. |
Use of low dose amount of spironolactone for treatment of cardiovascular disease
|
|
AR030414A1
(es)
*
|
2000-04-03 |
2003-08-20 |
Astrazeneca Ab |
Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
|
|
SE0002354D0
(sv)
*
|
2000-06-22 |
2000-06-22 |
Astrazeneca Ab |
New formulation
|
|
FI20010233A0
(fi)
*
|
2001-02-08 |
2001-02-08 |
Orion Corp |
Menetelmä sydämen vajaatoiminnan hoitoon
|
|
FI20011464A0
(fi)
*
|
2001-07-04 |
2001-07-04 |
Orion Corp |
Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
|
|
US7020521B1
(en)
|
2002-11-08 |
2006-03-28 |
Pacesetter, Inc. |
Methods and apparatus for detecting and/or monitoring heart failure
|
|
KR20120008093A
(ko)
|
2003-11-17 |
2012-01-25 |
노파르티스 아게 |
디펩티딜 펩티다제 ⅳ 억제제의 용도
|
|
US20060018970A1
(en)
*
|
2003-12-12 |
2006-01-26 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
|
|
EP1737448A1
(en)
*
|
2004-03-22 |
2007-01-03 |
Myogen, Inc. |
(s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
|
|
CA2560538A1
(en)
*
|
2004-03-22 |
2005-10-06 |
Myogen, Inc. |
(r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
|
|
EP1776108A1
(en)
*
|
2004-06-23 |
2007-04-25 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of pde-iii mediated diseases
|
|
EP1802775B1
(en)
*
|
2004-09-14 |
2010-05-26 |
The Regents of the University of Colorado |
Method for treatment with bucindolol based on genetic targeting
|
|
EP1888101B1
(en)
|
2005-06-06 |
2012-03-21 |
Georgetown University |
Compositions and methods for lipo modeling
|
|
EP1945242A2
(en)
*
|
2005-07-22 |
2008-07-23 |
The Regents of the University of Colorado, A Body Corporate |
Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure
|
|
US9512481B2
(en)
|
2009-09-11 |
2016-12-06 |
The Regents Of The University Of Colorado, A Body Corporate |
Polymorphisms in the PDE3A gene
|
|
US11083704B2
(en)
*
|
2017-01-03 |
2021-08-10 |
Bristol-Myers Squibb Company |
Method of administering nitroxyl donating compounds
|
|
EP4092013A1
(en)
|
2017-06-20 |
2022-11-23 |
Imbria Pharmaceuticals, Inc. |
Compositions and methods for increasing efficiency of cardiac metabolism
|
|
WO2020081361A1
(en)
|
2018-10-17 |
2020-04-23 |
Imbria Pharmaceuticals, Inc. |
Methods of treating rheumatic diseases using trimetazidine-based compounds
|
|
WO2020243120A1
(en)
|
2019-05-31 |
2020-12-03 |
Imbria Pharmaceuticals, Inc. |
Methods of treating fibrosis using compounds that promote glucose oxidation
|
|
EP4146215A4
(en)
*
|
2020-05-04 |
2024-05-01 |
Imbria Pharmaceuticals, Inc. |
DOSAGE METHODS FOR TREATMENT OF CARDIOVASCULAR PROBLEMS
|
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|